Ann: Quarterly Report and Appendix 4C, page-3

The MedAdvisor Board is pleased with the trajectory of the business and is forecasting FY22revenue of between $72-74 million with a gross margin around 53-54%. This outlook is basedon an exchange rate AUD:USD of $0.73. Based on the current trajectory, the Company alsoexpects to be in a cash positive position by mid CY22.

Shareholders should hold them accountable for that.......been a long long road for investors, and perversely its not the MDR software that is going to make/break this company (well the software is still not PBT positive!!), but really the health programs that drug companies are paying for (particularily in the US through Adheris) that is delivering. Revenues not recurring, but if they can get this flywheel started (pharmacies, patients/users, digital adoption and hence data), then it becomes easier to sell to the drug companies (still not as strong as the recurring reveues from pharmacies paying for medadvisor app, but a very critical tool for drug companies)